Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Recommendation of “Buy” by Brokerages

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have received a consensus recommendation of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $33.60.

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush raised their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CEO Sanj K. Patel sold 136,124 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the sale, the chief executive officer now owns 63,012 shares in the company, valued at $1,616,257.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Sanj K. Patel sold 136,124 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the transaction, the chief executive officer now directly owns 63,012 shares in the company, valued at $1,616,257.80. The disclosure for this sale can be found here. Insiders have sold a total of 260,564 shares of company stock worth $6,727,929 over the last quarter. Insiders own 54.57% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KNSA. Algert Global LLC lifted its position in Kiniksa Pharmaceuticals by 78.1% during the second quarter. Algert Global LLC now owns 18,603 shares of the company’s stock worth $347,000 after buying an additional 8,156 shares in the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals in the second quarter valued at about $177,000. Millennium Management LLC raised its stake in Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares during the period. Squarepoint Ops LLC grew its stake in shares of Kiniksa Pharmaceuticals by 84.0% in the 2nd quarter. Squarepoint Ops LLC now owns 24,845 shares of the company’s stock valued at $464,000 after buying an additional 11,344 shares during the period. Finally, Rubric Capital Management LP increased its holdings in shares of Kiniksa Pharmaceuticals by 10.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after buying an additional 223,094 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Up 0.9 %

NASDAQ KNSA opened at $25.39 on Friday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 232.00 and a beta of 0.33. The stock’s 50-day simple moving average is $24.83 and its two-hundred day simple moving average is $21.11. Kiniksa Pharmaceuticals has a twelve month low of $14.12 and a twelve month high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company had revenue of $108.30 million during the quarter, compared to analyst estimates of $90.60 million. During the same period in the prior year, the business posted ($0.02) EPS. The firm’s revenue was up 51.5% compared to the same quarter last year. On average, equities analysts expect that Kiniksa Pharmaceuticals will post -0.31 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.